{"id": "293985", "url": "https://fevir.net/resources/Evidence/293985", "meta": {"profile": ["http://hl7.org/fhir/uv/ebm/StructureDefinition/intervention-only-evidence"], "versionId": "9", "lastUpdated": "2025-10-07T17:12:54.639Z"}, "name": "Heart_failure_Intervention_Evidence_from_MAGICapp_313961", "title": "MAGIC-derived InterventionOnlyEvidence: Heart failure in SGLT2 inhibitors Group in Adults with type 2 diabetes", "author": [{"name": "Computable Publishing\u00ae: MAGIC-to-FEvIR Converter"}], "citeAs": "MAGIC-derived InterventionOnlyEvidence: Heart failure in SGLT2 inhibitors Group in Adults with type 2 diabetes [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing\u00ae: MAGIC-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 293985. Revised 2025-10-07. Available at: https://fevir.net/resources/Evidence/293985. Computable resource at: https://fevir.net/resources/Evidence/293985#json.", "status": "active", "contact": [{"telecom": [{"value": "support@computablepublishing.com", "system": "email"}]}], "copyright": "https://creativecommons.org/licenses/by-nc-sa/4.0/", "publisher": "Computable Publishing LLC", "relatesTo": [{"type": "part-of", "targetReference": {"type": "Composition", "display": "MAGICapp Conversion Report: SGLT2 inhibitors and GLP-1 RA for type 2 diabetes", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "system": "https://fevir.net/FLI", "value": "MAGIC-5288-j1Wqrn-conversion-report", "assigner": {"display": "Computable Publishing LLC"}}}}], "statistic": [{"quantity": {"value": 0.176}, "description": "Risk 17.6%", "statisticType": {"coding": [{"code": "STATO:0000607", "system": "https://fevir.net/sevco", "display": "proportion"}]}}], "identifier": [{"type": {"text": "FEvIR Object Identifier", "coding": [{"code": "ACSN", "system": "http://terminology.hl7.org/CodeSystem/v2-0203", "display": "Accession ID"}]}, "value": "293985", "system": "https://fevir.net/FOI", "assigner": {"display": "Computable Publishing LLC"}}, {"type": {"text": "outcomeId"}, "value": "313961", "system": "https://app.magicapp.org/#/guidelines"}, {"type": {"text": "picoId"}, "value": "85798", "system": "https://app.magicapp.org/#/guidelines"}, {"type": {"text": "sectionId"}, "value": "73215", "system": "https://app.magicapp.org/#/guidelines"}], "useContext": [{"code": {"code": "evidence-communication", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Evidence Communication"}, "valueCodeableConcept": {"coding": [{"code": "InterventionOnlyEvidence", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "InterventionOnlyEvidence"}]}}], "resourceType": "Evidence", "variableDefinition": [{"observed": {"type": "Group", "display": "SGLT2 inhibitors Group in Adults with type 2 diabetes", "reference": "Group/236949", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "MAGIC-5288-j1Wqrn-intervention-group-MAGIC-5288-j1Wqrn-intervention-85394-I-85798", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}, "description": "Adults with type 2 diabetes -- SGLT2 inhibitors", "variableRole": "population"}, {"observed": {"type": "EvidenceVariable", "display": "Hospital admission for heart failure", "reference": "EvidenceVariable/236968", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "MAGIC-5288-j1Wqrn-313961", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}, "description": "Heart failure", "variableRole": "outcome"}], "description": "This Evidence Resource is referenced in an example for the EBMonFHIR Implementation Guide."}